In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type

Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0020. Online ahead of print.ABSTRACTEMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51-60. 38061372.PMID:38560913 | DOI:10.7326/J24-0020

Source: Annals of Internal Medicine - April 1, 2024 Category: Internal Medicine Authors: Jin Ho Hwang Chi-Yuan Hsu Source Type: research